Literature DB >> 20357516

Individual life expectancy estimation using validated prognostic scores for patients with cancer of unknown primary.

Charles Ferté1, Nicolas Penel, Jacques Bonneterre, Antoine Adenis.   

Abstract

PURPOSE: To implement 3 published prognostic scores in an independent set of patients with cancer of unknown primary (CUP), and compare their performance on individual life expectancy prediction. PATIENTS AND
METHOD: The survival of 430 consecutive patients with CUP was measured after they had allocated to their prognostic group (good prognosis vs. poor prognosis) according to each prognostic score. Using a 2 x 2 contingency table, we measured the sensitivity, specificity, positive predictive value (PPV) and accuracy of each score in predicting individual outcome (survival <90 days or >180 days).
RESULTS: The median overall survival was 189 days (1-4,801 days). Survival was <90 days in 143/421 cases and >180 days in 208/413 cases. The three PPVs were within the same range for prediction of survival <90 days (from 43 to 49%) as well as for prediction of survival >180 days (from 70 to 80%), and underestimate individual life expectancy of 40-50% of the patients. None of the 3 scores appeared significantly better.
CONCLUSION: The main finding of this retrospective analysis is that the published prognostic scores cannot be used for rational decision making. Copyright 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2010        PMID: 20357516     DOI: 10.1159/000306137

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  6 in total

1.  Stent treatment of malignant gastric outlet obstruction: the effect on rate of gastric emptying, symptoms, and survival.

Authors:  Lene Larssen; Truls Hauge; Asle W Medhus
Journal:  Surg Endosc       Date:  2012-04-27       Impact factor: 4.584

Review 2.  Carcinoma of unknown primary with hepatic metastases: a need of judicious and contemplative diagnostic algorithm.

Authors:  Vikram Sai Shivaji; Joseph Charles Wilson; Noemi L Schmidt; Orpheus Kolokythas; Neeraj Lalwani
Journal:  Abdom Radiol (NY)       Date:  2020-07-06

3.  Unfavorable cancers of unknown primaries: presentation and prognostic factors. A population-based 8-year experience.

Authors:  Margareta Randén; Maria Helde-Frankling; Sara Runesdotter; Peter Gunvén
Journal:  Med Oncol       Date:  2013-09-18       Impact factor: 3.064

4.  Cost-effectiveness of adding cetuximab to platinum-based chemotherapy for first-line treatment of recurrent or metastatic head and neck cancer.

Authors:  Malek B Hannouf; Chander Sehgal; Jeffrey Q Cao; Joseph D Mocanu; Eric Winquist; Gregory S Zaric
Journal:  PLoS One       Date:  2012-06-20       Impact factor: 3.240

Review 5.  Prognostic and diagnostic value of spontaneous tumor-related antibodies.

Authors:  Sebastian Kobold; Tim Luetkens; Yanran Cao; Carsten Bokemeyer; Djordje Atanackovic
Journal:  Clin Dev Immunol       Date:  2010-12-23

6.  Performance status is the most powerful risk factor for early death among patients with advanced soft tissue sarcoma: the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (STBSG) and French Sarcoma Group (FSG) study.

Authors:  N Penel; M V Glabbeke; S Mathoulin-Pelissier; I Judson; S Sleijfer; B Bui; P Schoffski; M Ouali; S Marreaud; V Brouste; A Duhamel; P Hohenberger; J-Y Blay
Journal:  Br J Cancer       Date:  2011-04-19       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.